Watch a comprehensive, video-based review from leading experts in the field and download slides on the current and potential future role of multikinase inhibitors (MKI) in gastrointestinal cancers, glioblastoma, and sarcoma.
1.25 AMA PRA Category 1 Credit(s)™
Apr 30, 2019
Apr 30, 2020
Axel Grothey, MDWest Cancer Center
Memphis, Tennessee, United States
Giuseppe Lombardi, MDIstituto Oncologico Veneto
Olivier Mir, MD, PhD, MPHInstitut Gustave Roussy
University of Paris-Sud
- MKIs: Overview
- MKIs in colorectal cancer
- MKIs in hepatobiliary carcinoma
- MKIs in GIST/sarcoma
- MKIs in glioblastoma
This educational activity is designed for oncologists and other healthcare professionals involved/interested in the management of patients with gastrointestinal cancers, glioblastoma, and sarcoma.
After successful completion of this educational activity, participants should be able to:
- Discuss the role of MKIs in the treatment of various tumor types, including gastrointestinal cancers, recurrent advanced cholangiocarcinoma, glioblastoma, and sarcoma
- Implement treatment plans using multikinase inhibition in metastatic colorectal cancer (CRC), hepatocellular carcinoma (HCC), and sarcoma
- Analyze efficacy and safety data with MKI in gastrointestinal cancers, glioblastoma, and sarcoma
This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals, Inc.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete activity: 1.25 hours
To contact Postgraduate Institute for Medicine, please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Grothey has disclosed that he has received consulting fees from Array, Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb, Daiichi, Eisai, and Genentech. He has also performed contracted research for Array, Bayer Healthcare Pharmaceuticals, Eisai, and Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Lombardi has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Mir has disclosed that he has received consulting fees from Ipsen, Lundbeck, Pfizer, Roche, and Servier. He has also received fees for non–CME/CE services from Eli-Lilly, Janssen, Roche, and Vifor. He has performed contracted research for Blueprint Medicines. He has ownership interest (less than 5%) in Amplitude Surgical and Transgene. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.
Postgraduate Institute for Medicine planners and managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed:
- Angela Zimmermann, PhD (scientific content manager) – worked on non-CME certified projects in the last 12 months supported by AstraZeneca, Merck, Novartis, and Pfizer
- Susan McKinney – no relevant financial relationships
- Ronald Viggiani, MD (medical director) – worked on non-CME certified projects in the last 12 months supported by Pfizer
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.